Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N P Restifo

Showing results (91-100 of 97) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 97 results.
The Journal of Experimental Medicine|August 22, 2001
Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapyA van Elsas, R P Sutmuller, A A Hurwitz, et al.
Journal of the National Cancer Institute|December 23, 1998
Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigensS A Rosenberg, Y Zhai, J C Yang, et al.
Cancer Research|June 11, 1999
Recombinant virus vaccination against "self" antigens using anchor-fixed immunogensK R Irvine, M R Parkhurst, E P Shulman, et al.
Advances in Experimental Medicine and Biology|January 1, 1996
Host range restricted, non-replicating vaccinia virus vectors as vaccine candidatesB Moss, M W Carroll, L S Wyatt, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 22, 1999
Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccineS A Rosenberg, J C Yang, D J Schwartzentruber, et al.
Nature Medicine|March 21, 1998
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanomaS A Rosenberg, J C Yang, D J Schwartzentruber, et al.
Gene Therapy|May 29, 2015
Enhanced T-cell activation and differentiation in lymphocytes from transgenic mice expressing ubiquitination-resistant 2KR LAT moleculesA B Rodriguez-Peña, J Gomez-Rodriguez, R L Kortum, et al.
Pageof 10

Showing results (91-100 of 97) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 97 results.
The Journal of Experimental Medicine|August 22, 2001
Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapyA van Elsas, R P Sutmuller, A A Hurwitz, et al.
Journal of the National Cancer Institute|December 23, 1998
Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigensS A Rosenberg, Y Zhai, J C Yang, et al.
Cancer Research|June 11, 1999
Recombinant virus vaccination against "self" antigens using anchor-fixed immunogensK R Irvine, M R Parkhurst, E P Shulman, et al.
Advances in Experimental Medicine and Biology|January 1, 1996
Host range restricted, non-replicating vaccinia virus vectors as vaccine candidatesB Moss, M W Carroll, L S Wyatt, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 22, 1999
Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccineS A Rosenberg, J C Yang, D J Schwartzentruber, et al.
Nature Medicine|March 21, 1998
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanomaS A Rosenberg, J C Yang, D J Schwartzentruber, et al.
Gene Therapy|May 29, 2015
Enhanced T-cell activation and differentiation in lymphocytes from transgenic mice expressing ubiquitination-resistant 2KR LAT moleculesA B Rodriguez-Peña, J Gomez-Rodriguez, R L Kortum, et al.
Pageof 10